% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

  • daolag daolag Apr 19, 2013 4:53 PM Flag

    Special Note: Safety not ready yet

    Special Note Regarding Forward-Looking Statements
    This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, Dr. Mueller's statements in the second paragraph of this press release and statements regarding (i) Vertex’s plans to conduct additional studies of VX-661 to further evaluate its potential for late-stage development; (ii) Vertex’s expectation that it will obtain 24-week safety and efficacy data from its Phase 3 studies of VX-809 in combination with ivacaftor and submit an NDA to the FDA in 2014, (iii) Vertex’s plans to begin a 28-day study of VX-983 in combination with ivacator in the second half of 2013

    SortNewest  |  Oldest  |  Most Replied Expand all replies
83.23+3.52(+4.42%)Feb 12 4:00 PMEST